Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System PDF Download

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309212219
Category : Medical
Languages : en
Pages : 74

View

Book Description
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309212243
Category : Medical
Languages : en
Pages : 74

View

Book Description
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.

Author: Forum on Neuroscience and Nervous System Disorders
Publisher:
ISBN: 9780309381628
Category :
Languages : en
Pages : 74

View

Book Description
Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309292492
Category : Medical
Languages : en
Pages : 107

View

Book Description
Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309178282
Category : Medical
Languages : en
Pages : 128

View

Book Description
Biomarkers, or biological markers, are quantitative measurements that offer researchers and clinicians valuable insight into diagnosis, treatment and prognosis for many disorders and diseases. A major goal in neuroscience medical research is establishing biomarkers for disorders of the nervous system. Given the promising potential and necessity for neuroscience biomarkers, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened a public workshop and released the workshop summary entitled Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. The workshop brought together experts from multiple areas to discuss the most promising and practical arenas in neuroscience in which biomarkers will have the greatest impact. The main objective of the workshop was to identify and discuss biomarker targets that are not currently being aggressively pursued but that could have the greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders.

Author: Firas H. Kobeissy
Publisher: CRC Press
ISBN: 1466565993
Category : Medical
Languages : en
Pages : 718

View

Book Description
With the contribution from more than one hundred CNS neurotrauma experts, this book provides a comprehensive and up-to-date account on the latest developments in the area of neurotrauma including biomarker studies, experimental models, diagnostic methods, and neurotherapeutic intervention strategies in brain injury research. It discusses neurotrauma mechanisms, biomarker discovery, and neurocognitive and neurobehavioral deficits. Also included are medical interventions and recent neurotherapeutics used in the area of brain injury that have been translated to the area of rehabilitation research. In addition, a section is devoted to models of milder CNS injury, including sports injuries.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309215366
Category : Medical
Languages : en
Pages : 203

View

Book Description
This report illustrates the work of IOM committees in selected, major areas in recent years, followed by a description of IOM's convening and collaborative activities and fellowship programs. The last section provides a comprehensive bibliography of IOM reports published since 2007.

Author: John W. DenBoer
Publisher: FriesenPress
ISBN: 1525547119
Category : Medical
Languages : en
Pages : 152

View

Book Description
This is Dementia: Disrupting the Decline seeks to dispel the myths surrounding dementia. It invites you to take a journey to explore the misconceptions, stereotypes, and various perspectives surrounding this devastating disorder. This journey is an interactive one that requires you to engage. It asks you to bring, and challenge, your own perspectives and understandings of what dementia is. The reality is that dementia in and of itself is not a disease. At its core, dementia is accelerated aging of the brain. In other words, the brain is on a faster trajectory toward death when compared to the body. This understanding of dementia is important as it opens the possibility of disrupting, even preventing, this trajectory. This is Dementia offers crucial insights into how dementia impacts our brains and its ability to function. It provides information on the early often imperceptible changes, referred to as Mild Cognitive Impairment (MCI), that can begin as early as 30 or 40 years old. It dispels the myths that dementia is an inevitable part of aging and that it is not treatable. It offers five steps -- Awareness, Acceptance, Action, Allowance, and Attitude -- to guide your understanding of dementia and prepare you for your own diagnosis or that of someone close to us. Regardless of if you or a loved one have been diagnosed with dementia or not, This is Dementia provides a road map to empower you to slow, maybe even stop, the seemingly relentless march of this debilitating, "take-everything-from-you" disorder.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309373263
Category : Medical
Languages : en
Pages : 107

View

Book Description
The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop.

Author: Pradeep C. Bollu
Publisher: Springer Nature
ISBN: 3031078977
Category : Medical
Languages : en
Pages : 320

View

Book Description
This book offers a comprehensive overview of the most important neurochemicals and approaches everything from the neurochemical’s perspective. It attempts to integrate the biochemical pathways of synthesis and metabolism of these neurochemicals with the disease states and point out the avenues of diagnostic testing and therapeutic intervention. Each chapter focuses on a specific neurochemical and provides a brief history, the biochemical profile, metabolism, physiological functions, and the clinical aspects. The clinical part of each chapter includes a discussion on disease states with either increased or reduced activity of the neurochemical and either activation or inhibition of the relevant receptors. This book is targeted toward practitioners and students of neuroscience and is written to emphasize the importance of these neurochemicals in the brain. With this emphasis on background neurochemical processes, the readers will be pointed towards logical diagnostic studies, laboratory investigations, and therapies based on the neurochemical dysfunction that underlies various disease states.